The desmoid tumor proteome: identifying molecular markers using a clinically annotated tissue microarray. Shohrae Hajibashi, Wei-Lien Wang, Alexander J.F. Lazar, Daniel Tuvin, Carla L. Warneke, Dolores Lopez-Terrada, Raphael E. Pollock, Dina Lev. Sarcoma Research Laboratory Houston, TX.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Shohrae Hajibashi, Wei-Lien Wang, Alexander J.F. Lazar, Daniel Tuvin, Carla L. Warneke, Dolores Lopez-Terrada, Raphael E. Pollock, Dina Lev
Sarcoma Research Laboratory
TMA: ~98% of the desmoids showed nuclear reactivity
Specific mutations in the -catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors
Am J Path. 173(5):1518-27; Nov 2008
1. “Up front” identification of potential desmoid-related/specific over-expressed genes
2. Confirm that gene over-expression leads to protein over production (TMA; different samples)
3. Validate these proteins as prognostic markers
4. Examine as possible targets for therapy
Human exonic evidence based oligonucleotide (HEEBOChip) microarray
10 desmoid tumor samples (20 additional specimens;
van de Rijn/West; Stanford)
2. Confirm that gene over-expression leads to protein over production (TMA)
ADAM12 protein: disintegrin
and metalloprotease; up-regulated in many human cancers
Role in tumor progression
resistance to apoptosis
Actin3 & 4. Examine ADAM12 as a prognostic marker; possible target for (future) desmoid therapy?
ADAM12 over-expressed in desmoid cell cultures
Anti-ADAM12 agents in pipe line…